<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386344</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15294</org_study_id>
    <secondary_id>2017-002041-30</secondary_id>
    <secondary_id>U1111-1195-6371</secondary_id>
    <nct_id>NCT03386344</nct_id>
  </id_info>
  <brief_title>Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control</brief_title>
  <acronym>SOTA-BONE</acronym>
  <official_title>A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the superiority of sotagliflozin dose 1 versus placebo with respect to
      hemoglobin A1c (Hb1Ac) reduction in patients with type 2 diabetes (T2D) who have inadequate
      glycemic control on diet and exercise only or with a stable antidiabetes regimen.

      Secondary Objectives:

        -  To compare the effects of sotagliflozin dose 1 and dose 2 versus placebo with respect to
           the percent change in bone mineral density (BMD) at lumbar spine, total hip, and femoral
           neck, measured by dual-energy X-ray absorptiometry (DXA).

        -  To demonstrate the superiority of sotagliflozin dose 1 versus placebo on change in body
           weight (BW), fasting plasma glucose (FPG), systolic blood pressure (SBP) for all
           patients; and to evaluate the proportion of patients with a HbA1C &lt;7%.

        -  To demonstrate the superiority of sotagliflozin dose 2 versus placebo with respect to
           HbA1c reduction; change in BW, FPG, and SBP for all patients; and to evaluate the
           proportion of patients with HbA1c &lt;7.0%.

        -  To evaluate the safety of sotagliflozin dose 1 and dose 2 compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 110 weeks (Screening period of up to 2 weeks,
      2 week single-blind run-in period), a 26-week double-blind core treatment period, a 78-week
      double-blind extension period, and a 2- week post treatment follow up period.

      DXA scans will be performed to assess Bone Mineral Density and Fat vs. Lean body mass at
      baseline and Weeks 26, 52, and 104.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1C (HbA1c)</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Absolute change from baseline to Week 26 HbA1c (for sotagliflozin dose 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Absolute change from Baseline to Week 26 in HbA1c comparing sotagliflozin dose 2 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (BW)</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Absolute change from Baseline to Week 26 in BW (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Absolute change from Baseline to Week 26 in FPG (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure (SBP)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Absolute change from Baseline to Week 12 in SBP in all patients (dose 1 and dose 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with HbA1c &lt; 7.0%</measure>
    <time_frame>At Week 26</time_frame>
    <description>Percentage of patients with HbA1c &lt; 7.0% at Week 26 (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in bone mineral density (BMD) of lumbar spine</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Percent change in BMD of lumbar spine at week 26 (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in BMD of total hip</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Percent change in BMD of total hip at week 26 (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in BMD of femoral neck</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Percent change in BMD of femoral neck at week 26 (doses 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Absolute number of patients with adverse events up to week 104 (doses 1 and 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotagliflozin dose 1 given as two (2) dose 2 sotagliflozin tablets on top of baseline antidiabetic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotagliflozin dose 2 given as one (1) dose 2 sotagliflozin tablet and one (1) sotagliflozin matching placebo tablet on top of baseline antidiabetic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, given as two (2) sotagliflozin matching placebo tablets on top of baseline antidiabetic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: Tablet
Route of administration: Oral</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Tablet
Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patients with Type 2 Diabetes (T2D) managed with diet and exercise only or with a
             stable antidiabetes regimen (in monotherapy or combination therapy that can include
             oral antidiabetes medications, insulin, or glucagon-like peptide-1 agonists) for more
             than 12 weeks.

          -  Patient has given written informed consent to participate in the study in accordance
             with local regulations.

        Exclusion criteria:

          -  Age &lt;55 years.

          -  Women who have been postmenopausal (or undergone bilateral oophorectomy) for less than
             5 years.

          -  Type 1 diabetes mellitus.

          -  Body mass index (BMI) ≤20 or &gt;45 kg/m2 or body weight that exceeds the weight limits
             of the Dual-energy X-ray absorptiometry (DXA) scanner.

          -  Hemoglobin A1C (HbA1c) &lt;7.0% or HbA1c &gt;11.0%.

          -  Use of a selective sodium-glucose cotransporter type 2 (SGLT2) inhibitor or
             thiazolidinedione within 24 months.

          -  Bone mineral density (BMD) T- score &lt;-2.0 at any site (ie, lumbar spine, total hip, or
             femoral neck).

          -  History of fracture within 12 months (except for fractures of the hand/fingers,
             foot/toes, facial bones, and skull).

          -  Treatment with medications known to affect bone mass or modify the risk of fractures
             within 36 months (eg, bisphosphonates, selective estrogen receptor modulators,
             calcitonin, teriparatide, denosumab, strontium ranelate, growth hormone, aromatase
             inhibitors, androgen deprivation therapy, carbamazepine, phenytoin, and
             phenobarbital). Use of hormonal replacement that includes systemic or transdermal
             estrogen or testosterone is excluded unless is stable for at least 24 months prior to
             Screening.

          -  Lower extremity complications (such as skin ulcers, infection, osteomyelitis and
             gangrene) identified during the Screening period, and still requiring treatment at
             Randomization.

          -  Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such
             as heart failure, active cancer, or other conditions that the Investigator believes
             with result in a short life expectancy.

          -  Renal disease as defined by an estimated glomerular filtration rate (eGFR) &lt;30
             mL/min/1.73m² at the Screening Visit by the 4 variable Modification of Diet in Renal
             Disease equation.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8409009</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409010</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409005</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409012</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409014</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205-1138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409015</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409002</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409001</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401-6638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409008</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409004</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409013</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8409007</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249003</name>
      <address>
        <city>Brampton</city>
        <zip>L6S 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249005</name>
      <address>
        <city>Pointe-Claire</city>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249006</name>
      <address>
        <city>Thornhill</city>
        <zip>L4J 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249004</name>
      <address>
        <city>Thornhill</city>
        <zip>L4K 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249007</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Y 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1249002</name>
      <address>
        <city>Victoriaville</city>
        <zip>G6P 3Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

